life sciences tools

Instruments, reagents and consumables for research labs and drug makers.

Industry · 8 companies · 6 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

Role
  • ANT Anthropic

    Supplies it“Provides computational biologists, bioinformaticians, clinical trial managers, and regulatory affairs specialists with domain intelligence built into frontier models across organic chemistry, structural biology, lab protocols, and bioinformatics pipelines.”

    Latest 424B4final IPO prospectusMixedControlled company ·

    Sells Claude AI models and coding tools; $81.3B offering funds compute expansion

  • BRKR Bruker

    Sells it 92%, $3.2B a year“We are a developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions that enable our customers to explore life and materials at microscopic, molecular and cellular levels.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • CDNA CareDx, Inc

    Sells it 13%, $48.4M a year“We develop, manufacture, market and sell products that increase the chance of successful transplants by facilitating a better match between a solid organ or stem cell donor and a recipient, and help provide post-transplant surveillance.”

    Latest 10-QQ3 FY2026Positive ·

    Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

    • Revenue$139.4MYoY +39.3%
    • Net income$19.3Mvs $1.7M year ago
  • COHR Coherent Corp.

    Supplies it, part of Industrial Segment“Applications within the biotechnology segment include research and diagnostic tools such as flow cytometry, genome sequencing, and PCR, to name a few.”

    Latest 8-KPositiveBuyback ·

    Authorized up to $2.0B in share repurchases through open-market trades, negotiated deals or derivatives.

  • DHR Danaher Corporation

    Sells it 28%, $1.9B a quarter“Core sales grew 4.5%, driven by consumables and, to a lesser extent, equipment.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • GLW Corning Inc.

    Sells it 5%, $247.0M a quarter“Life Sciences and Emerging Growth Businesses incurred higher losses, reflecting emerging-business R&D and, for 9M, Pharmaceutical Technologies.”

    Latest 10-QQ3 FY2026PositiveImpairment / chargeLegal / investigation ·

    Generative-AI demand powers Optical Communications growth and customer-backed U.S. capacity expansion.

    • Revenue$4.9BYoY +18.4%
    • Net income$680.0MYoY +58.1%
  • TMO Thermo Fisher Scientific

    Sells it 36%, $16.1B a year“Through our Life Sciences Solutions segment, we provide an extensive portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease.”

    Latest 8-KLeadership change ·

    Executive Vice President Michael D. Shafer will retire effective Dec. 31, 2026.

  • TWST Twist Bioscience

    Sells it 100%, $459.4M a year“We have developed multiple products and solutions derived from synthetic DNA and our versatile DNA synthesis technology.”

    Latest 10-KFY2026Positive ·

    AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.

    • Revenue$459.4MYoY +22.0%
    • Net income−$130.2MYoY −67.6%

Feedback